NYSE:NVTA - InVitae Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $24.12 -0.17 (-0.70 %) (As of 03/26/2019 10:44 AM ET)Previous Close$24.29Today's Range$23.77 - $24.5952-Week Range$4.35 - $25.76Volume11,279 shsAverage Volume2.30 million shsMarket Capitalization$1.85 billionP/E Ratio-12.37Dividend YieldN/ABeta2.23 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It also operates Patient Insights Networks, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform that is used for the collection, analysis, and management of patient family history information. Invitae Corporation serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California. Receive NVTA News and Ratings via Email Sign-up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVTA Previous Symbol CUSIPN/A CIK1501134 Webwww.invitae.com Phone415-374-7782Debt Debt-to-Equity Ratio0.47 Current Ratio4.56 Quick Ratio4.56Price-To-Earnings Trailing P/E Ratio-12.37 Forward P/E Ratio-13.33 P/E GrowthN/A Sales & Book Value Annual Sales$147.70 million Price / Sales12.54 Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book11.12Profitability EPS (Most Recent Fiscal Year)($1.94) Net Income$-129,350,000.00 Net Margins-87.58% Return on Equity-88.93% Return on Assets-50.99%Miscellaneous Employees788 Outstanding Shares76,810,000Market Cap$1.85 billion Next Earnings Date5/8/2019 (Estimated) OptionableOptionable InVitae (NYSE:NVTA) Frequently Asked Questions What is InVitae's stock symbol? InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA." How were InVitae's earnings last quarter? InVitae Corp (NYSE:NVTA) posted its quarterly earnings results on Tuesday, February, 19th. The medical research company reported ($0.40) EPS for the quarter, beating the Zacks' consensus estimate of ($0.42) by $0.02. The medical research company earned $45.36 million during the quarter, compared to analyst estimates of $40.87 million. InVitae had a negative net margin of 87.58% and a negative return on equity of 88.93%. View InVitae's Earnings History. When is InVitae's next earnings date? InVitae is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for InVitae. What guidance has InVitae issued on next quarter's earnings? InVitae updated its FY 2019 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $220-220 million, compared to the consensus revenue estimate of $200 million.InVitae also updated its FY 2018 guidance to EPS. What price target have analysts set for NVTA? 6 analysts have issued 1 year target prices for InVitae's stock. Their forecasts range from $20.00 to $29.00. On average, they expect InVitae's share price to reach $22.25 in the next twelve months. This suggests that the stock has a possible downside of 8.1%. View Analyst Price Targets for InVitae. What is the consensus analysts' recommendation for InVitae? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InVitae. Has InVitae been receiving favorable news coverage? News headlines about NVTA stock have trended somewhat negative this week, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. InVitae earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of InVitae's key competitors? Some companies that are related to InVitae include Guardant Health (GH), ELEKTA AB/ADR (EKTAY), Genomic Health (GHDX), CareDx (CDNA), Natera (NTRA), Veracyte (VCYT), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Fulgent Genetics (FLGT), PotNetwork (POTN), Miragen Therapeutics (MGEN), Psychemedics (PMD), First Choice Healthcare Solutions (FCHS) and CBA Florida (CBAI). What other stocks do shareholders of InVitae own? Based on aggregate information from My MarketBeat watchlists, some companies that other InVitae investors own include NVIDIA (NVDA), ITT Educational Services (ESINQ), Twilio (TWLO), Progenics Pharmaceuticals (PGNX), Celgene (CELG), Alibaba Group (BABA), Gilead Sciences (GILD), Roku (ROKU), Cisco Systems (CSCO) and ACADIA Pharmaceuticals (ACAD). Who are InVitae's key executives? InVitae's management team includes the folowing people: Dr. Randal W. Scott, Exec. Chairman (Age 61)Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 45)Ms. Shelly D. Guyer, Chief Financial Officer (Age 59)Mr. Lee Bendekgey, Sec. & COO (Age 61)Ms. Laura D'Angelo, Head of Investor Relations When did InVitae IPO? (NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers. Who are InVitae's major shareholders? InVitae's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.17%), Perceptive Advisors LLC (2.50%), Orbimed Advisors LLC (1.11%), Northern Trust Corp (1.06%), Geode Capital Management LLC (0.93%) and Geode Capital Management LLC (0.93%). Company insiders that own InVitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Eric Aguiar, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Institutional Ownership Trends for InVitae. Which institutional investors are selling InVitae stock? NVTA stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Bank of America Corp DE, MetLife Investment Advisors LLC, Barclays PLC, Bank of New York Mellon Corp, Bank of Montreal Can and Gabelli Funds LLC. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Insider Buying and Selling for InVitae. Which institutional investors are buying InVitae stock? NVTA stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Investments LP, BlackRock Inc., Amundi Pioneer Asset Management Inc., Fiera Capital Corp, Daiwa SB Investments Ltd., Citigroup Inc. and D. E. Shaw & Co. Inc.. Company insiders that have bought InVitae stock in the last two years include Bros Advisors Lp Baker and Randal W Scott. View Insider Buying and Selling for InVitae. How do I buy shares of InVitae? Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is InVitae's stock price today? One share of NVTA stock can currently be purchased for approximately $24.20. How big of a company is InVitae? InVitae has a market capitalization of $1.86 billion and generates $147.70 million in revenue each year. The medical research company earns $-129,350,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. InVitae employs 788 workers across the globe. What is InVitae's official website? The official website for InVitae is http://www.invitae.com. How can I contact InVitae? InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected] MarketBeat Community Rating for InVitae (NYSE NVTA)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 313 (Vote Outperform)Underperform Votes: 331 (Vote Underperform)Total Votes: 644MarketBeat's community ratings are surveys of what our community members think about InVitae and other stocks. Vote "Outperform" if you believe NVTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/26/2019 by MarketBeat.com StaffFeatured Article: Why is a lock-up period needed for an IPO?